{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "DecreaseAmount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P22897",
      "entity_text" : "MMR",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "CellLine" : [ "cellosaurus:CVCL_Y548" ],
      "Species" : [ "taxonomy:9606" ],
      "CellType" : [ "cl:CL:0000034" ]
    }
  },
  "verbose_text" : "The largest discontinuation study to date, the European stop TKI (EURO-SKI) trial has recently reported a molecular recurrence-free survival of 52% (CI : 48-56%) in 750 CP CML patients treated with imatinib, nilotinib, or dasatinib at 24 months, using loss of MMR as the criteria for relapse.",
  "reading_complete" : "2020-08-04T10:01:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T09:57:39Z",
  "trigger" : "loss",
  "evidence" : [ "loss of MMR" ],
  "pmc_id" : "5402174",
  "score" : 0
}